Appointments
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Executives On The Move: Kite Pharma Announces Its Next CEO And A Trio Of VPs For Tilray
T-cell therapy firm Kite Pharma announces a former Eli Lilly VP as its next CEO. Over at Canadian pharma and cannabis business Tilray, three new VPs for Europe in expansion, marketing and commercial development.
Executives On The Move: EIP Pharma Acquires Talent From Shire, And Arvinas And Selvita Fill Top Medical Spots
CNS-focused therapeutics developer EIP Pharma adds former Shire VP as CFO. And new CMOs for protein-degradation therapeutics firm Arvinas and European drug discovery business Selvita.
Asia Executives On The Move: Returners And Leavers At Merck; Changes At Takeda, Ono, Simcere And More
Merck China former R&D head returns after a short stint with startup Ascletis, and Takeda has a new center director for commercial health. Top executives change also take place at Ono in Korea and Simcere Pharma.
Executives On The Move: Amgen Biologics Head Joins Immusoft; Julphar Poaches From Novartis, AbbVie And Mylan
Executives On The Move: Exits At AbbVie And Shire Pharma, And A Regional Leadership Appointment At Acino
AbbVie medical exec now holds CMO position at vaccines company Vaccitech, and Shire Pharma head of international commercial picked for CEO of protein-misfolding firm Orphazyme. Swiss pharma Acino International appoints former Novartis services head as General Manager, Latin America.
Asia Executives On The Move: Changes At Pfizer, Lilly, Alexion, Healios
The coming of summer has brought a flurry of executive changes in the Asia-Pacific health sector. Pfizer China's head of R&D is leaving while Lilly and Alexion in Japan have new presidents.
Executives On The Move: Alnylam Decides On Next CFO, Annexon Picks A CBO And Eli Lilly Announces A New Area President
At Alnylam a new CFO is in place. Annexon Biosciences chooses as CBO a Johnson & Johnson Innovation leader and Eli Lilly & Co promotes exec to SVP and President, Lilly Bio-Medicines.
Executives On The Move: New Hires In Finance, Science and Leadership At Zimmer, ObsEva And Roche Korea
Former Bristol-Myers Squibb exec takes CFO spot at Zimmer Biomet and Swiss reproductive health company ObsEva to bring on new CMO. Plus Roche Korea oncology head is now CEO of LEO Pharma Korea.
Executives On The Move: Comings And Goings At MorphoSys And PDL BioPharma, Along With Board Changes At Entasis And Sutro
A new CEO will join MorphoSys AG and the CFO of PDL BioPharma is set to depart. Also, precision antibacterial company Entasis Therapeutics and cancer and autoimmune therapy firm Sutro Biopharma each elect a Chairman.
Asia Executives On The Move: BMS Names New China GM, New President For Nippon Kayaku
The coming of summer has seen a flurry of executive changes in the Asia Pacific biopharma sector. BMS has named a new China GM amid a fierce immuno-oncology battle, Parexel Japan has a new president, and other personnel changes take place at Nippon Kayaku, Zai Lab and Harbour BioMed.
Executives On The Move: This Week We Highlight Leadership Appointments At Eiger, Reckitt Benckiser And Roche
Eiger BioPharma gains regulatory talent with new VP, global regulatory affairs. UK multinational health and hygiene firm Reckitt Benckiser hires PepsiCo leader as CEO and Roche adds new head of group communications.
Executives On The Move: Changes At Amgen, Novartis and EyePoint
Amgen commercial lead takes up top sales post at Adamas Pharmaceuticals and a Novartis Oncology VP switches to SVP, Americas Commercial Oncology at Eisai Inc. Also, EyePoint Pharma announces its new chief commercial officer is now on board.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.